Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts.

du Manoir JM, Francia G, Man S, Mossoba M, Medin JA, Viloria-Petit A, Hicklin DJ, Emmenegger U, Kerbel RS. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 1):904-16.

View in: PubMed

subject areas

Angiogenesis Inhibitors
Animals
Antibodies, Monoclonal
Breast Neoplasms
Cell Line, Tumor
Cell Proliferation
Cyclophosphamide
Disease Models, Animal
Drug Evaluation, Preclinical
Drug Resistance, Neoplasm
Female
Gene Expression Regulation
Humans
Mice
Receptor, erbB-2
RNA, Messenger
Sensitivity and Specificity
Time Factors
Tumor Cells, Cultured
Vascular Endothelial Growth Factor A
Xenograft Model Antitumor Assays

authors with profiles

Giulio Francia

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support